Tatiana Drewiacki

Tatiana Drewiacki, MD, MBA, currently serves as a Senior Clinical Scientist at Galderma, where responsibilities include collaborating on safety reviews, developing medical presentations, and managing periodic benefit-risk evaluation reports. Previous roles comprise serving as a Risk-Based Quality Management Coordinator, leading the RBQM strategy for the nemolizumab program, and managing clinical operations teams at ICON plc for COVID-19 monoclonal antibodies. Tatiana has held significant positions in medical affairs and clinical management at notable companies such as IQVIA, Pfizer, Bayer Health Care, and Roche. With a strong educational background including a Doctor of Medicine from USP and an MBA from FGV, Tatiana also has experience in research and has contributed to published work in respiratory physiology.